TNFSF11 and Familial prostate cancer: Recently, a new drug blocking RANK/RANKL/OPG pathway exerts bone control with the prevention of bone resorption and destruction: denosumab, a fully human monoclonal antibody (anti-RANKL), authorized for the treatment/prevention of SREs in bone metastases from MM, breast, prostate cancer and Ewing Sarcoma.